(Q30925583)

27 June 2017

0 references

1 reference

title

Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data (English)

1 reference

27 June 2017

0 references

1 reference

3

1 reference

27 June 2017

Craig J Whittington

1

0 references

author name string

Tim Kendall

2

1 reference

27 June 2017

David Cottrell

4

1 reference

27 June 2017

Andrew Cotgrove

5

1 reference

27 June 2017

Ellen Boddington

6

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

363

1 reference

27 June 2017

issue

9418

1 reference

27 June 2017

page(s)

1341-1345

1 reference

The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Psychosocial treatments for adolescent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Drug company experts advised staff to withhold data about SSRI use in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Treatment of major depressive disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Synthesising licensing data to assess drug safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

1 reference

7 January 2021

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916043-1

7 January 2021

10.1016/S0140-6736(04)16043-1

Identifiers

DOI

1 reference

27 June 2017

1 reference